admin – Page 4189 – Get News Story

Collaborative Home Care Enhances Senior Well-Being with 24-Hour Care in Stamford, CT.

Supporting families with compassionate, private 24-hour home care solutions tailored for Stamford’s senior community.

Stamford, CT – Collaborative Home Care, a trusted name in senior care, proudly announces its continued dedication to providing compassionate private 24-hour home care in Stamford, CT. This initiative underscores the company’s commitment to enhancing the quality of life for seniors and their families by offering personalized, around-the-clock care tailored to the unique needs of Stamford’s aging population.

“At Collaborative Home Care, we believe that every senior deserves to live with dignity and respect, no matter their health challenges,” said Bryan Knust, owner of Collaborative Home Care. “Our 24-hour home care services are designed to deliver the highest standard of compassionate care, ensuring peace of mind for families while promoting the independence and well-being of their loved ones.”

With the growing demand for private 24-hour home care in Stamford, CT, Collaborative Home Care emphasizes providing tailored solutions for seniors with chronic conditions, cognitive impairments, or disabilities. The care model integrates professional caregiving expertise with a compassionate approach, ensuring seniors can remain in the comfort and safety of their homes while receiving continuous support.

Families should consider 24-hour home care for their loved ones for several reasons. First, it provides unparalleled safety and security for seniors, especially those at risk of falls, wandering, or medical emergencies. Around-the-clock supervision ensures immediate response in critical situations, significantly reducing risks and providing peace of mind to family members.

Second, 24-hour care offers personalized attention and support, which can greatly improve a senior’s quality of life. Caregivers can assist with activities of daily living, medication management, meal preparation, and mobility, ensuring the senior’s physical and emotional needs are met consistently and with care.

Finally, 24-hour home care allows families to maintain balance and avoid caregiver burnout. Caring for a senior loved one can be physically and emotionally taxing. Professional care enables family members to focus on their personal well-being while ensuring their loved ones receive top-notch support from experienced professionals.

Families in Stamford seeking reliable home care solutions can benefit from:

Comprehensive 24-hour care services, including assistance with daily activities and medical needs.
A team of highly trained, compassionate caregivers dedicated to meeting individualized care plans.
Flexible care options designed to provide relief to family members and ensure seniors’ comfort.

For more information about Collaborative Home Care and their 24-hour care in Stamford, CT, please visit their website at https://collaborativehomecare.com

About Collaborative Home Care:

Collaborative Home Care is a premier provider of personalized home care services in Stamford, CT. Dedicated to delivering exceptional care, the company focuses on fostering independence, comfort, and well-being for seniors and their families. With a team of skilled caregivers and a compassionate approach, Collaborative Home Care remains a trusted partner in the community, offering support that truly makes a difference.

Media Contact
Company Name: Collaborative Home Care
Contact Person: Bryan Knust
Email: Send Email
Phone: +12035422808
Address:777 West Putnam Avenue
City: Greenwich
State: CT
Country: United States
Website: https://collaborativehomecare.com/

Discover the Power of Change and Self-Discovery in Noreen Doran’s New Book, Lil Rock’s Journey: A Metaphorical Tale of Living Through Change

Feb 6, 2025 – Noreen Doran, Ph.D., is proud to announce the release of her latest book, Lil Rock’s Journey: A Metaphorical Tale of Living Through Change, a compelling story that invites readers to explore the profound themes of change, resilience, and self-discovery through the eyes of an unlikely heroine—Lil Rock.

In this beautifully crafted metaphorical tale, readers are introduced to Lil Rock, a small yet resilient stone who unexpectedly finds herself swept away from her familiar surroundings into the vast, unpredictable currents of life. As she navigates the twists and turns of the river, Lil Rock learns to embrace the unknown, trust her inner voice, and discover the strength within herself to grow and evolve.

Lil Rock’s Journey is more than just a story; it is a universal metaphor for the challenges and opportunities that come with change. Whether readers are experiencing a personal transformation, facing unforeseen challenges, or simply seeking inspiration, Lil Rock’s adventure offers valuable insights and lessons on how to navigate life’s currents with grace and courage.

Key Themes and Features:

A Metaphor for Personal Growth: The river in Lil Rock’s journey symbolizes the flow of life, encouraging readers to trust the process, adapt to change, and find their own path forward.
Resilience and Inner Strength: Lil Rock’s story highlights the importance of resilience in the face of adversity and the power of listening to one’s inner voice, even when the journey is uncertain.
Self-Discovery: As Lil Rock journeys through the river, she uncovers deeper truths about herself and her place in the world, reflecting the universal human experience of self-discovery.
Beautifully Illustrated: The book features captivating illustrations that bring Lil Rock’s journey to life, making it a visual and emotional experience for readers of all ages.

About the Author

Noreen enjoyed a teaching career that included kindergarten through college. She received the prestigious “Teacher of the Handicapped Award” through Rotary International and received her Master’s degree in Education at the University of York, England. After starting a family, she began working on her PhD in Human Development. It was then that Lil Rock surfaced into her mind. She wrote a metaphorical tale of a rock that went on an unexpected adventure that showed her depth of understanding of Human Development theory. Needless to say, this story held a sweetness in her heart and has been revised heavily for today’s version. Currently, Noreen can be found mountain biking, hiking, kayaking, traveling, reading, or writing fiction.

Book Name: Lil Rock’s Journey

Author Name: Noreen Doran Ph.D

ISBN Number: 1917438893

Kindle Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Books Publishing Company
Email: Send Email
Phone: +1-213-734-5718
Address:2425 West Loop South
City: Houston
State: Texas
Country: United States
Website: https://bookspublishingcompany.com

Rising Staff: Connecting Talent with Real Opportunities in the U.S. Job Market

The Future of Workforce Efficiency in Logistics and Manufacturing

In today’s fast-paced economy, efficiency and reliability are the cornerstones of success for warehouses and production lines. The ability to build a strong, skilled workforce is not just an operational need—it’s a strategic advantage. Rising Staff is at the forefront of this transformation, providing innovative human resource solutions that empower businesses and workers alike.

The Workforce Driving the U.S. Supply Chain

Warehouses and production facilities are the backbone of the global supply chain, ensuring that goods reach their destinations on time. These industries require a dependable, highly motivated workforce that can adapt to evolving demands. Rising Staff bridges this gap by strategically sourcing and placing qualified talent where it’s needed most.

Unlike traditional staffing agencies, Rising Staff goes beyond simple placements. By understanding the unique challenges of logistics and manufacturing, we craft workforce solutions tailored to each company’s needs. Our approach reduces turnover, boosts productivity, and ensures that businesses remain competitive in an increasingly demanding market.

Why Rising Staff is the Go-To HR Partner for Warehouses and Production Lines

Hiring is no longer just about filling positions—it’s about optimizing performance. Rising Staff partners with businesses to provide seamless workforce solutions that align with long-term operational goals. Our expertise in logistics and production staffing ensures that companies can access the right talent at the right time.

From seasonal hiring surges to long-term workforce planning, we anticipate market trends and proactively address labor shortages. By leveraging data-driven insights and industry expertise, we streamline hiring processes, helping businesses reduce costs and increase efficiency.

A Smarter and More Strategic Approach to Workforce Management

At Rising Staff, we believe that people are the key to business success. Our recruitment strategies are designed to match the right talent with the right roles, creating a win-win situation for both employers and employees. We eliminate inefficiencies in the hiring process, allowing companies to focus on growth while ensuring workers have opportunities that support career advancement.

Rising Staff: Redefining Workforce Solutions for a Competitive Economy

As the demand for skilled, reliable workers in logistics and manufacturing continues to rise, Rising Staff remains a trusted leader in workforce solutions. We are not just filling positions—we are driving industry growth, ensuring that businesses thrive and workers find meaningful, rewarding careers.

For companies looking to strengthen their workforce and job seekers eager to advance their careers, Rising Staff is the strategic partner that delivers results. The future of workforce management is here, and we are leading the way.

Media Contact
Company Name: Rising Staff
Email: Send Email
Phone: 2394091633
Country: United States
Website: http://risingstaff.com/

New Book Offers Groundbreaking Insights and Strategies for Managing ADHD

Feb 6, 2025 – Psychotherapist, Supervisor, ADHD Coach, and NLP Master Practitioner Nea Clark has released her highly anticipated new book, Travel into the ADHD: Mind Strategies for Working with ADHD Clients. This essential guide is designed to help therapists, counselors, and non-professionals alike gain a deeper understanding of ADHD, offering practical strategies to support neurodivergent individuals in managing their condition and thriving in their personal and professional lives.

In Travel into the ADHD, Clark combines years of clinical experience with the latest research on neurodiversity, delivering a comprehensive framework that blends psychology with real-world applications. The book is packed with actionable insights, including a 12-step treatment program that empowers professionals to work confidently with ADHD clients while also providing individuals with practical tools for managing their daily challenges.

“ADHD is one of the most misunderstood conditions in the mental health field,” says Clark. “Through this book, I aim to demystify the complexities of ADHD and provide both professionals and individuals with a clear, methodical approach to managing it. Whether you’re a therapist, a parent, or someone living with ADHD, there’s something here to help you navigate the challenges and live a more fulfilling life.”

About the Author

Nea Clark is a Psychotherapist, Supervisor, and ADHD Coach with several years of experience working with ADHD clients and supervisees. She is passionate about enabling practitioners to work confidently with ADHD individuals, helping them develop the skills needed to manage neurodivergence. Clark is also an advocate for neurodiversity, promoting awareness and understanding through her work and public speaking.

In Travel into the ADHD, Clark shares her personal and professional journey with ADHD, offering insights into how neurodiversity affects brain function, behavior, and emotional well-being. Her book is designed to help both professionals and individuals improve their lives by understanding and embracing neurodiversity.

Book Name: Travel into the ADHD Mind

Author Name: Nea Clark

ISBN Number: 1917438664

Kindle Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co

Biocompatible Coatings Market, Size, Analytical Overview, CAGR, Growth Factors, Demand and Trends Forecast to 2028

“Browse 200 market data Tables and 70 Figures spread through 300 Pages and in-depth TOC on “Biocompatible Coatings Market””

The Biocompatible Coatings market is driven by rising demand in medical implants, pharmaceuticals, and biotechnology. Key players include Surmodics, Materion, DSM, and Covalon, focusing on innovation and advanced coating technologies. With ongoing R&D, the market is poised for steady growth, ensuring safer and more effective biomedical applications.

The report “Biocompatible Coatings Market by Type (Antibacterial, hydrophilic), Material (Polymer, Ceramics, Metal), End-Use Industry (Healthcare, Food & Beverage, Medical Devices), & Region (APAC, Europe, North America, MEA & SA) – Global Forecast to 2028”, size is estimated at USD 14.6 billion in 2022 to USD 29.7 billion by 2028, at a CAGR of 12.4%, between 2023 and 2028. The market research report provides access to critical information such as biocompatible coatings market growth drivers, market growth restraints, current market trends, the market’s economic and financial structure, and other key market details. The rapid growth of the healthcare industry, Rapid urbanization, population growth, and the increasing focus on hygiene and cleanliness drive the biocompatible coatings market. The biocompatible coatings market is divided into five key regions:Asia Pacific, Europe, North America, Europe, the Middle East & Africa, and South America. China and India, among other countries, are fastest growing biocompatible coatings market globally.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32624649

The demand for biocompatible coatings is influenced by several factors. One crucial factor is the increasing focus on healthcare and medical advancements. With the continuous progress in medical technology and the growing emphasis on patient well-being, there is a higher demand for biocompatible coatings in various applications. These coatings play a vital role in enhancing the biocompatibility of medical devices, implants, and prosthetics, reducing the risk of adverse reactions and improving patient outcomes. The aging population and the prevalence of chronic diseases drive the demand for medical devices and implants, which, in turn, fuels the demand for biocompatible coatings. The companies have adopted various strategies, such as mergers & acquisitions, investment & expansion, joint ventures, & new product launches and to increase their global presence and maintain sustained growth in the biocompatible coatings market.

Polymer segment is expected to account for the largest share in 2022.

Polymers provide versatility, allowing for the development of coatings with tailored properties such as biocompatibility, durability, flexibility, and resistance to wear and corrosion. These characteristics make polymer coatings suitable for a diverse range of medical devices and implants, including orthopedic implants, cardiovascular stents, surgical instruments, and drug delivery systems. advancements in polymer technology have enabled the development of biodegradable coatings. These coatings gradually dissolve or degrade over time, reducing the need for additional surgical interventions to remove the coating. Bioresorbable polymer coatings are particularly advantageous for implantable devices, as they can facilitate tissue healing and integration. The widespread adoption of polymer-based biocompatible coatings can be attributed to their compatibility with various fabrication techniques, cost-effectiveness, and well-established manufacturing processes. These factors make polymer coatings more accessible and easier to integrate into existing medical device production workflows.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=32624649

Food & Beverage segment is expected to account for the largest share in 2022.

The food and beverage segment is a crucial component of the biocompatible coatings industry, and it plays a vital role in ensuring the safety, quality, and shelf life of food and beverage products. Food and beverage packaging serves as a protective barrier that safeguards products from external factors such as moisture, light, air, and contaminants. It helps prevent spoilage, maintain product freshness, and extend shelf life. Advanced packaging materials and technologies, including biocompatible coatings, are employed to ensure optimal product protection and preservation. the food and beverage packaging segment is driven by the need for product protection, safety, branding, convenience, sustainability, and regulatory compliance. Biocompatible coatings play a significant role in enhancing the safety, functionality, and aesthetics of packaging materials in this segment, meeting the evolving demands of both consumers and regulatory bodies.

Asia Pacific is expected to register highest CAGR during the forecast period.

Asia Pacific region has a large and rapidly growing population, along with increasing healthcare expenditure. This demographic trend drives the demand for medical devices, implants, and related technologies, which in turn fuels the need for biocompatible coatings. The region’s rising middle class and improving healthcare infrastructure also contribute to the market growth.

There is a growing focus on medical tourism in countries like India, Thailand, and Malaysia, where patients from other countries seek medical treatments. This trend further drives the demand for advanced medical devices and implants, which often require biocompatible coatings. the region’s manufacturing capabilities and cost advantages attract global medical device manufacturers to establish production facilities in Asia Pacific countries. This factor supports the local production and consumption of biocompatible coatings, further contributing to market growth.

Biocompatible Coatings Market Companies

The major players in the global biocompatible coatings market are SurModics, Inc. (US), DSM Biomedical (US), Hydromer Inc. (US), Covalon Technologies Ltd. (Canada), and Hemoteq AG (Germany). These players opted for inorganic growth through mergers & acquisitions, agreements, and partnerships. For instance, in July 2021, SurModics, Inc. has acquired privately-held Vetex Medical Limited. The Galway, Ireland-based medical device developer and manufacturer has focused exclusively on venous clot removal solutions.

SurModics, Inc: SurModics, Inc. is a global provider of surface modification and in vitro diagnostic technologies. The company is headquartered in Eden Prairie, Minnesota, United States. SurModics has been operating for over four decades and has established itself as a leader in the field of biocompatible coatings and surface modification technologies. The company’s core focus is on developing and commercializing innovative solutions that enhance the performance, biocompatibility, and functionality of medical devices. SurModics offers a broad portfolio of biocompatible coatings designed to address various applications and industries, including cardiovascular, ophthalmology, neurology, and in-vitro diagnostics. SurModics’ biocompatible coatings provide functionalities such as lubricity, hydrophilicity, drug delivery, anti-thrombogenicity, and bioactive capabilities. These coatings are tailored to meet the specific requirements of medical devices, ensuring improved performance, reduced complications, and enhanced patient outcomes. SurModics collaborates with medical device manufacturers, pharmaceutical companies, and diagnostic testing laboratories to develop customized coating and surface modification solutions. The company’s team of scientists and engineers work closely with customers to understand their specific needs and deliver innovative solutions that address their challenges.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=32624649

In April 2020, Cook Medical and Surmodics, Inc. have announced a new distribution agreement in which Cook Medical will market two novel Surmodics products, hydrophilic percutaneous transluminal angioplasty (PTA) balloon catheters that may be utilised beyond 0.014-inch and 0.018-inch wire guides.

DSM Biomedical: DSM Biomedical is a division of DSM, a global science-based company headquartered in the Netherlands. DSM Biomedical specializes in developing and manufacturing biomedical materials and technologies, with a focus on providing innovative solutions for the medical device and healthcare industries. The company offers a wide range of products and solutions that address various medical applications, including orthopedics, cardiovascular devices, dental applications, drug delivery systems, and wound care. DSM Biomedical’s expertise lies in developing biocompatible materials, coatings, drug delivery systems, and regenerative solutions that enhance the performance, biocompatibility, and safety of medical devices. The company places a strong emphasis on sustainability and environmental responsibility. DSM Biomedical strives to develop materials and technologies that are eco-friendly and have minimal impact on the environment. This commitment aligns with the growing demand for sustainable solutions in the medical industry.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biocompatible-coating-market-32624649.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biocompatible Coatings Market, Size, Analytical Overview, CAGR, Growth Factors, Demand and Trends Forecast to 2028

Myelofibrosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight’s, “Myelofibrosis Pipeline Insight” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Myelofibrosis Pipeline Report to explore emerging therapies, key Myelofibrosis Companies, and future Myelofibrosis treatment landscapes @ Myelofibrosis Pipeline Outlook Report

Key Takeaways from the Myelofibrosis Pipeline Report

In January 2025:- Sumitomo Pharma America Inc.:- This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
In January 2025:- Keros Therapeutics Inc.:- KER-050 is an investigational therapeutic protein designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias including anemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF)
In January 2025:- Geron Corporation:- The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
In January 2025:- Karyopharm Therapeutics Inc.:- This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b).
In January 2025:- Ryvu Therapeutics SA:- The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.
DelveInsight’s Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
The leading Myelofibrosis Companies such as Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.

Discover how the Myelofibrosis treatment paradigm is evolving. Access DelveInsight’s in-depth Myelofibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Myelofibrosis Clinical Trials and Studies

Myelofibrosis Emerging Drugs Profile

Imetelstat: Geron Corporation

Imetelstat sodium (imetelstat) is a small oligonucleotide composed of a nucleic acid and a lipid moiety. The proprietary nucleic acid backbone provides resistance to degradation, thus conferring improved stability in plasma and tissues, as well as significantly improved binding affinity to its target. The lipid group enhances cell permeability, which results in increased potency and improved pharmacokinetic and pharmacodynamic properties.

Bomedemstat: Merck

Bomedemstat is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme critical for regulating the proliferation of hematopoietic stem cells and the maturation of progenitors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myelofibrosis.

TL-895: Telios Pharma, Inc.

It is an orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myelofibrosis.

RVU120: Ryvu Therapeutics SA

RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor developed by Ryvu Therapeutics. RVU120’s mechanism of action (MoA) involves targeting CDK8/19 kinases. Specifically, translational data confirm the proposed MoA in a molecularly-defined subset of patients with DNMT3A and NPM1 mutations. Currently, the drug is in the Phase II stage of development to treat Myelofibrosis.

TBX-2400: Taiga Biotechnologies, Inc.

TBX-2400 is an allogeneic stem cell therapy developed by Taiga Biotechnologies that aims to improve the rate of engraftment and reconstitution of the immune system for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Currently, the drug is in the Phase I stage of development to treat Myelofibrosis.

Get a detailed analysis of the latest innovations in the Myelofibrosis pipeline. Explore DelveInsight’s expert-driven report today! @ Myelofibrosis Unmet Needs

Myelofibrosis Companies

Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Myelofibrosis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Myelofibrosis Therapies and key Myelofibrosis Developments @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Myelofibrosis Pipeline Report

Coverage- Global
Myelofibrosis Companies- Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Myelofibrosis drug development? Find out in DelveInsight’s exclusive Myelofibrosis Pipeline Report—access it now! @ Myelofibrosis Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Myelofibrosis: Overview
Myelofibrosis Pipeline Therapeutics
Myelofibrosis Therapeutic Assessment
Myelofibrosis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Imetelstat: Geron Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
RVU120: Ryvu Therapeutics SA
Drug profiles in the detailed report…..
TBX-2400: Taiga Biotechnologies, Inc.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelofibrosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

Polyurethane Catalyst Market Segmentation and Growth Opportunities through 2028 | Expert Review and Forecast

“Browse 191 market data Tables and 45 Figures spread through 205 Pages and in-depth TOC on “Polyurethane Catalyst Market””

The polyurethane catalyst market is driven by rising demand in construction, automotive, and furniture industries. Key players like BASF, Covestro, Evonik, and Huntsman focus on innovation and sustainability. With increasing adoption of eco-friendly catalysts, the market is set for steady growth, shaping the future of polyurethane applications globally.

The Polyurethane catalyst Market is projected to reach USD 3.1 Billion by 2028, at a CAGR of 6.0% from USD 2.3 Billion in 2023. The market growth is driven by factors such as the rapid urbanization and infrastructure development, advancements in manufacturing processes and global energy efficiency initiatives. This research report covers major aspects of the industry including polyurethane catalyst market drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable).

Polyurethane Catalyst Companies

The key players in this market are BASF SE Germany), Evonik Industries AG (Germany), Huntsman International LLC (US), Momentive (Niskayuna), Tokyo Chemical Industry Co., Ltd. (Japan), DOW (US), Tosoh Corporation (Japan), Carpenter Co. (US), Mofan Polyurethane CO., LTD. (China), UMICORE (Brussels). These companies are strong in their home regions and explore geographic diversification alternatives to grow their businesses. They focus on increasing their market shares through new product launches and other expansions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=118466262

BASF SE

BASF SE, headquartered in Ludwigshafen, Germany, is a global leader in the chemical industry. Founded in 1865, the company has evolved into one of the world’s largest chemical producers, serving a diverse range of industries. With a commitment to creating sustainable solutions, BASF engages in the development, manufacturing, and distribution of a vast portfolio of chemicals, materials, and technologies. Spanning sectors such as agriculture, automotive, construction, consumer goods, and healthcare, BASF’s innovative products contribute to numerous aspects of modern life.

The company is operating across various segments, BASF caters to a multitude of industries. The “Chemicals” segment produces foundational and specialty chemicals, while the “Materials” segment focuses on performance materials like plastics and foam products. “Industrial Solutions” offers diverse solutions for industries ranging from agriculture to construction, and “Surface Technologies” provides coatings for sectors like aerospace and manufacturing. “Nutrition & Care” delivers ingredients for personal care, nutrition, and pharmaceuticals, and “Agricultural Solutions” supports sustainable agriculture.

BASF SE has established a widespread geographic presence, with operations spanning across regions and continents. The company’s global footprint enables it to serve a diverse range of markets and customers. BASF’s presence extends to North America, Europe, Asia Pacific, and other parts of the world. The company operates numerous production sites, research and development facilities, and offices in key locations, ensuring its ability to deliver products and solutions to customers around the globe.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=118466262

Evonik Industries AG

Headquartered in Essen, Germany, Evonik Industries AG is a prominent player in the global chemical industry, specializing in specialty chemicals and high-performance materials. Formed in 2007, the company has rapidly established itself as a leading provider of innovative solutions across various sectors. Evonik’s operations are organized into distinct operating segments tailored to specific industries: “Nutrition & Care” offers ingredients for human and animal nutrition, personal care, and healthcare; “Resource Efficiency” provides solutions for energy efficiency and sustainability in industries such as automotive and construction; “Performance Materials” specializes in high-performance polymers and materials for sectors like automotive and electronics; “Smart Materials” focuses on unique materials like superabsorbents and membranes for agriculture and water treatment; and “Technology & Infrastructure” offers products like silica and silanes for infrastructure and technical applications.

Evonik’s geographic presence is widespread, reflecting its commitment to serving global markets. In Europe, the company boasts a strong presence with manufacturing sites, research centers, and offices. North America is another significant region for Evonik, hosting production facilities and research centers. The company strategically positions itself in Asia Pacific, with operations in China, Japan, and Singapore to tap into the region’s dynamic growth. Evonik serves the Latin American market through production sites and sales offices, while also extending its reach to the Middle East and Africa, contributing to local industries and regional development.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=118466262

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polyurethane Catalyst Market Segmentation and Growth Opportunities through 2028 | Expert Review and Forecast

10 tips for preparing for a Spanish test

Taking a Spanish test is a key step in starting a new course in a precise way. The result of the test is accurate and will allow direct access to the appropriate level for each student to make the most of the learning. Having an enriching experience and getting the most out of a Spanish course in Spain is easy and simple after taking a Spanish level test.

It is one of the most widely spoken languages in the world, in countries all over the globe, and it is growing by leaps and bounds every day. That is why a student who decides to learn Spanish as a second language is making a key decision for their future. But before starting to study the language, it is crucial to find out the level of knowledge so that the course can be adapted to the student’s needs.

Below, these ten tips for tackling a Spanish level test like the one at Don Quijote with confidence and obtaining the most accurate assessment possible, which will help the student to embark on a unique and practical journey in the language.

Familiarize with the format of the Spanish test

Each Spanish test is different, and its structure can vary, so preparing before taking one is crucial. Knowing the characteristics in advance is advisable to know what the student is up against. Some Spanish level tests include multiple choice questions, grammar exercises, reading and listening comprehension, or even an oral part.

It is therefore important to review examples of similar tests, which will help to reduce uncertainty and improve performance in the test. Because many students get nervous and fail easy questions that they do know.

Review key grammar and vocabulary concepts

It is always a good idea to review the grammar structures of the language. Verbs in their most used tenses, prepositions, pronouns or, in the case of Spanish, gender and number agreement. All these categories are fundamental aspects that appear in any level test.

Likewise, reinforcing common vocabulary will facilitate the understanding of texts and questions. Ideally, the content and knowledge that the student has already acquired should be reviewed, so that the test result will be closer to reality.

Doing practice exercises

Making use of online resources or specific exercise books will allow the student to consolidate their knowledge and identify areas for improvement. Once the test confirms the categories where the student needs to improve, the Spanish course they take can focus on reinforcing those areas.

The more questions answers in conditions like those of the Spanish test, the more comfortable they will be when they take the official Spanish test. Therefore, it is advisable to take as many Spanish level tests as possible that are very similar to the one the student is going to take.

Listen to Spanish regularly

Listening comprehension is usually part of some Spanish tests. Therefore, exposure to the language is also an essential part. Listening to podcasts, series, news or videos on digital platforms will help train the ear and adapt to the language. It is advisable to choose materials with different accents to get used to the variations of the language, always on topics that interest the student, so that they can better grasp the subject matter and vocabulary.

Read in Spanish every day

Reading is an excellent way to reinforce grammar and expand vocabulary. Books, newspaper articles, blogs or essays in Spanish provide exposure to common syntactic structures and idiomatic expressions. In addition, daily practice will strengthen the ability to understand texts quickly.

Practice writing frequently

Writing short texts or answering questions in writing, even keeping a personal diary, will improve their written expression in Spanish. In addition, writing short compositions on various topics and revising the grammar will help consolidate the knowledge and improve the level of Spanish day by day.

Prepare the oral part if necessary

If the test includes an interview or an oral part, practicing with native speakers or fellow students will be very useful. Expressing yourself out loud about everyday topics, describing experiences or giving opinions will allow the student to gain fluency and confidence in speaking Spanish.

Time management

Distributing the time in a balanced way is key to completing all sections of the test without rushing. Although most Spanish level tests do not usually have a time limit, it is necessary to know how to manage the time so as not to get stuck on a particular question.

Reading each question carefully, answering the simplest ones first and leaving the most complex ones until last can be an effective strategy. If possible, setting aside a few minutes to review the answers will ensure greater accuracy.

Stay calm and trust in the acquired knowledge

Nerves can play tricks on the student but maintaining a positive attitude and trusting in the level of Spanish they have acquired will help them to face the test with greater peace of mind. Taking deep breaths before starting and remembering that the test only seeks to place them at the appropriate level on the course will help to reduce anxiety.

Don’t obsess over perfection

Making mistakes is part of the learning process. The important thing is to communicate ideas clearly and make progress in mastering the language, without getting stuck for fear of making mistakes. Therefore, it doesn’t matter if the level test is full of mistakes, because the goal is to achieve an optimal level and, to do so, a Spanish course in Spain is the key.

Following this advice will make it easier to prepare for the level test and will allow the student to access the most appropriate Spanish course. The key is in perseverance and practice, thus ensuring a better adaptation to the learning process in Spain.

Media Contact
Company Name: Don Quijote Spanish School
Contact Person: Press Office
Email: Send Email
Country: Spain
Website: https://www.donquijote.org/

Hemophilia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight’s, “Hemophilia Pipeline Insight” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Hemophilia Companies, and future Hemophilia treatment landscapes @ Hemophilia Pipeline Outlook Report

Key Takeaways from the Hemophilia Pipeline Report

In January 2025:- Staidson (Beijing) Biopharmaceuticals Co., Ltd:- This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.
In January 2025:- ApcinteX Ltd:- The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of prophylactic SerpinPC administered subcutaneously (SC) to participants with severe hemophilia A (HemA) (with or without inhibitors) or moderately severe to severe hemophilia B (HemB) (without inhibitors) as part of the SerpinPC registrational program.
In January 2025:- Novo Nordisk A/S- This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups.
In January 2025:- Pfizer:- To establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. To establish baseline prospective efficacy data of current FVIII prophylaxis replacement therapy in the usual care setting of hemophilia A subjects, who are negative for nAb to AAV6, prior to the Phase 3 gene therapy study. The enrollment for hemophilia A participants is completed. At this time participants are only being enrolled for hemophilia B cohort.
In January 2025:- CSL Behring- This study will investigate the pharmacokinetics (PK), efficacy, and safety of rIX-FP for the routine prophylaxis of bleeding episodes in male Chinese previously treated patients (PTPs) with hemophilia B (FIX activity of ≤ 2%). In addition to the scheduled rIX-FP prophylaxis regimen, subjects may also receive rIX-FP episodic (on-demand) treatment for breakthrough bleeding episodes and rIX-FP for the prophylaxis and treatment of bleeding in emergency surgical procedures.
In January 2025:- Octapharma:- Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment
DelveInsight’s Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Promising Hemophilia Therapies such as ELOCTA, ALPROLIX, Mim8, NNC0365-3769, MG1113, STSP-0601 for Injection, SerpinPC, Fitusiran, Esperoct andothers.

Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight’s in-depth Hemophilia Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies

Hemophilia Emerging Drugs Profile

SerpinPC: Centessa Pharmaceuticals

SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.

Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.

ASC 618: ASC Therapeutics

ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.

Get a detailed analysis of the latest innovations in the Hemophilia pipeline. Explore DelveInsight’s expert-driven report today! @ Hemophilia Unmet Needs

Hemophilia Companies

Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Hemophilia Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives

Scope of the Hemophilia Pipeline Report

Coverage- Global
Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Hemophilia Therapies- ELOCTA, ALPROLIX, Mim8, NNC0365-3769, MG1113, STSP-0601 for Injection, SerpinPC, Fitusiran, Esperoct andothers.
Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight’s exclusive Hemophilia Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Hemophilia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hemophilia– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Fitusiran: Alnylam Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SerpinPC: Centessa Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Hemophilia Key Companies
Hemophilia Key Products
Hemophilia- Unmet Needs
Hemophilia- Market Drivers and Barriers
Hemophilia- Future Perspectives and Conclusion
Hemophilia Analyst Views
Hemophilia Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

Corrosion Protection Coatings Market Growth Analysis: Key Drivers, Trends, and Forecasts from Recent Research

“Browse 258 market data Tables and 66 Figures spread through 299 Pages and in-depth TOC on “Corrosion Protection Coatings Market””

The Corrosion Protection Coatings Market is driven by growing demand in industries like oil & gas, marine, and infrastructure. Key players include AkzoNobel, PPG Industries, Sherwin-Williams, and Jotun, focusing on advanced, eco-friendly coatings. Innovation in water-based and high-performance coatings will shape future market growth.

The Corrosion Protection Coatings market is projected to grow to USD 12.4 billion by 2028 from USD 10.4 billion in 2023, at a CAGR of 3.5% between 2023-2028. Rising demand for efficient processes and longer life of equipment in the industrial sectors boosts the Corrosion Protection Coatings market. This research report covers major aspects of the industry including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview withCorrosion Protection Coatings market growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable).

Opportunities: Emerging countries offer significant growth opportunities

The emerging markets of corrosion protection coatings such as China, India, Thailand, and Brazil offer high growth opportunities for the players in the market. Currently, these countries account for the lowest per-capita consumption of coatings in the world and thus offer the potential for growth. Opportunities for market growth in these countries have further increased due to the development of their domestic industries which are consuming corrosion protection coatings significantly. Major players such as PPG Industries (US) and AkzoNobel (Netherlands) have restructured their strategies by placing high importance on penetrating and creating bases in these emerging markets.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150815310

Epoxy is the largest segment of the overall Corrosion protection coatings market.

Epoxy-based corrosion protection coatings have been widely used and are in high demand in various industries. Epoxy coatings are known for their excellent corrosion resistance and durability, making them suitable for applications in sectors such as infrastructure, marine, and oil and gas. Such coatings offer durability, versatility, adhesion, ease of application, and aesthetics along with good corrosion resistance. In many end-use industries, there are strict regulations and standards regarding corrosion protection. Epoxy coatings often meet or exceed these requirements, ensuring compliance and maintaining the integrity of structures or equipment.

Water-based technology is the fastest-growing segment in the market during the forecast period.

Water is the main solvent in the water-based corrosion prevention coatings technology. Up to 80% of the coating is made of water. Therefore, when employing this technology, a solvent is not needed. In accordance with US and European laws, it produces fewer VOCs, which are less than 3.5 pounds per gallon of water, making it environmentally friendly.

To increase the performance of water-based coatings over solvent-based coatings and lower the cost of production, this technology is continuously developing. Currently, water-based corrosion protection coatings are costlier than solvent-based corrosion protection coatings. Polyacrylates, polyvinyl ethers, and polyurethane resins serve as the coating technology’s binder materials.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150815310

Asia Pacific is the largest market for Corrosion Protection coatings globally during the forecast period

The global market for corrosion protection coatings is expanding at the quickest rate in Asia Pacific. Economic growth, followed by significant investment in a variety of sectors, including petrochemical, oil & gas, infrastructure, power generation, and industrial, are primarily responsible for this. The most potential market is in Asia Pacific, and it is likely to be the case in the foreseeable future. Additionally, to take advantage of the cheap labor and meet local market demand, international businesses are moving their production plants to Asia Pacific.

Corrosion Protection Coatings Companies

Major players in the global Corrosion Protection Coatings market have made many research breakthroughs across the value chain to focus on shifting client demands. Mergers and acquisitions, partnerships and agreements, and new product launches have all occurred at the companies. Some of the prominent market participants include Akzo Nobel NV (Netherlands), PPG Industries, Inc. (US), Jotun A/S (Norway), The Sherwin-Williams Company (US), and Kansai Paint Co., Ltd. (Japan).

AkzoNobel N.V. is a a diversified chemical company operating its business through two major segments, namely, Decorative Coatings and Performance Coatings. Corrosion protection coating is produced under both segments. AkzoNobel N.V. has a strong customer base and operates in countries in Europe, North America, Asia Pacific, South America, and the Middle East. The company has over 28 manufacturing facilities and sales activities in more than 150 countries across the globe. It has a wide product portfolio which includes brands such as Dulux, Sikkens, Butanox, Elotex, International, and Interpon.

PPG Industries Inc. is a global manufacturer and supplier of paints, coatings, optical products, and specialty materials. It serves customers in the industrial, consumer products, transportation, and construction markets. PPG provides industrial and automotive coatings to manufacturing companies, adhesives & sealants to the automotive industry, metal pretreatments & related chemicals for industrial and automotive applications, and packaging coatings to aerosol, food & beverage container manufacturers. The company also delivers protective coating solutions for a wide range of industries. It has 156 manufacturing facilities worldwide. The company operates through two major segments, namely, Performance Coatings and Industrial Coatings. The company offers corrosion protection coatings through the Performance Coatings segment.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=150815310

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Corrosion Protection Coatings Market Growth Analysis: Key Drivers, Trends, and Forecasts from Recent Research